MedTrace Logo

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

NCT05756556 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-02-01

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.

Conditions

Interventions

COMBINATION_PRODUCT

T3011 + Cobimetinib

1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)

Sponsors & Collaborators

  • ImmVira Pharma Co. Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-12-31
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05756556 on ClinicalTrials.gov